Biostar Pharmaceuticals, Inc.
BSPM · OTC
12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |
|---|---|---|---|---|
| Revenue | $2 | $27 | $61 | $53 |
| % Growth | -91.2% | -55.8% | 16.5% | – |
| Cost of Goods Sold | $1 | $16 | $31 | $27 |
| Gross Profit | $1 | $11 | $30 | $26 |
| % Margin | 38.4% | 40.9% | 49.3% | 48.7% |
| R&D Expenses | $1 | $4 | $3 | $3 |
| G&A Expenses | $2 | $5 | $8 | $6 |
| SG&A Expenses | $4 | $13 | $26 | $23 |
| Sales & Mktg Exp. | $1 | $9 | $18 | $17 |
| Other Operating Expenses | -$0 | $5 | $3 | -$1 |
| Operating Expenses | $4 | $35 | $32 | $25 |
| Operating Income | -$4 | -$24 | -$1 | $1 |
| % Margin | -149.5% | -87.6% | -2.1% | 1% |
| Other Income/Exp. Net | $1 | -$0 | $3 | $0 |
| Pre-Tax Income | -$3 | -$24 | $2 | $3 |
| Tax Expense | $3 | $1 | -$3 | $2 |
| Net Income | -$6 | -$25 | $5 | $1 |
| % Margin | -239% | -92.6% | 7.9% | 1.5% |
| EPS | -2.5 | -11.36 | 2.3 | 0.49 |
| % Growth | 78% | -593.9% | 369.4% | – |
| EPS Diluted | -2.5 | -11.36 | 2.3 | 0.49 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $2 | $3 | $3 |
| EBITDA | -$2 | -$21 | $5 | $6 |
| % Margin | -71.2% | -78.1% | 7.8% | 11% |